Public-registry site landscape for NCT07699471, “A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism”, a Hypoparathyroidism study sponsored by MBX Biosciences. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07699471 (registry record) |
| Study title | A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism |
| Official title | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label Extension to Evaluate the Safety and Efficacy of Canvuparatide (MBX 2109) in Adult Patients With Hypoparathyroidism |
| Sponsor | MBX Biosciences |
| Condition(s) | Hypoparathyroidism |
| Phase | PHASE3 |
| Listed sites | 2 |
| Intervention(s) | Canvuparatide |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT07699471.
Eichor generates a preliminary site-risk snapshot for NCT07699471 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
